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Abstract
Background: Apolipoprotein E (ApoE) is a molecular scavenger in the blood and brain. Aberrant
function of the molecule causes formation of protein and lipid deposits or "plaques" that
characterize Alzheimer's disease (AD) and atherosclerosis. There are three human isoforms of
ApoE designated ε2, ε3, and ε4. Each isoform differentially affects the structure and function of the
protein and thus the development of disease. Homozygosity for ApoE ε4 is associated with
atherosclerosis and Alzheimer's disease whereas ApoE ε2 and ε3 tend to be protective.
Furthermore, the ε2 form may cause forms of hyperlipoproteinemia. Therefore, introduction of
ApoE ε3 may be beneficial to patients that are susceptible to or suffering from these diseases.
Mesenchymal stem cells or multipotent mesenchymal stromal cells (MSCs) are adult progenitor
cells found in numerous tissues. They are easily expanded in culture and engraft into host tissues
when administered appropriately. Furthermore, MSCs are immunosuppressive and have been
reported to engraft as allogeneic transplants. In our previous study, mouse MSCs (mMSCs) were
implanted into the brains of ApoE null mice, resulting in production of small amounts of ApoE in
the brain and attenuation of cognitive deficits. Therefore human MSCs (hMSCs) are a promising
vector for the administration of ApoE ε3 in humans.
Results: Unlike mMSCs, hMSCs were found not to express ApoE in culture; therefore a molecular
screen was performed for compounds that induce expression. PPARγ agonists, neural stem cell
conditioned medium, osteo-inductive media, dexamethasone, and adipo-inductive media (AIM)
were tested. Of the conditions tested, only AIM or dexamethasone induced sustained secretion of
ApoE in MSCs and the duration of secretion was only limited by the length of time MSCs could be
sustained in culture. Upon withdrawal of the inductive stimuli, the ApoE secretion persisted for a
further 14 days.
Conclusion: The data demonstrated that pre-treatment and perhaps co-administration of MSCs
homozygous for ApoE ε3 and dexamethasone may represent a novel therapy for severe instances
of AD, atherosclerosis and other ApoE-related diseases.
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Apolipoprotein E is a 34 kDa secreted lipoprotein, first
discovered by Shore and Shore in 1973, see reference 1.
Like other apolipoproteins, its primary function is to scav-
enge cholesterol, associated lipids and proteins for trans-
port to the liver for processing. In healthy individuals, a
plasma concentration of approximately 5 mg/dL is suffi-
cient to maintain systemic lipid homeostasis [2].
Although primarily expressed in liver [1], ApoE contrasts
with the other apolipoproteins in that it is also expressed
in the spleen, lungs, kidneys, myoblasts, and macro-
phages [2,3]. ApoE is also highly expressed in the brain,
by microglia and astrocytes [3,4] and there have also been
reports of ApoE production by neurons [3]. Although
poorly understood, the role of ApoE in the central nervous
system is thought to be comparable to its role in plasma,
sequestering cholesterol, lipids and other macromolecu-
lar debris from neural tissue [5].
The effectiveness of ApoE as a lipid scavenger is closely
related to the ApoE isoform. ApoE polymorphism is
thought to be uniquely exhibited by humans [3] in that it
consists of three isoforms, ApoE ε2, ε3, and ε4. Although
the isoforms vary only at two amino acid residues, the
changes are sufficient to profoundly alter the tertiary
structure and affect lipid binding properties of the protein
[3,5]. ApoE polymorphism occurs at residues 112 and
158, ApoEε2 has two cysteines, ApoEε3 had a cysteine and
an arginine and ApoEε4 has two arginines at these posi-
tions. ApoE ε3 is the most common isoform with an inci-
dence of approximately 77% in the population [1,3,4],
followed by ε4 in approximately 15%, and then ε2 at
approximately 7%.
Due to the profound effects on the functional and struc-
tural properties of the protein, different isoforms of ApoE
are associated with different diseases such as stroke, mul-
tiple sclerosis, Parkinson's disease, alcoholic cirrhosis of
the liver and type 2 diabetes [3,6-8]. The role that ApoE
isoforms play in disease development seems to be closely
associated with different affinities of the various isoforms
for the low density lipoprotein-receptor and lipids them-
selves. For instance in the case of Alzheimer's disease
(AD), individuals that are homozygous or heterozygous
for ApoE ε4, have a significantly increased risk of develop-
ing the disease with an earlier onset [3] compared with
individuals with the most common ApoE ε3/ε3 genotype
[1,3,4,9-11]. Likewise, individuals homozygous for Apo
ε2 or with an ApoE ε2/ε3 genotype also have normal sus-
ceptibility for AD. Although ApoE4 is not an absolute
determinant of the disease 40–65% of AD patients have at
least one copy of the 4 allele. However, the role of ApoE
isoforms is complex with additional reports also implicat-
ing ApoE ε2 with hyperlipidaemia and ApoE ε4 with
hypercholesterolaemia. [9,12]. In consideration of the
putative association of ApoE ε2 and ε4 with disease it is
reasonable to assume that safe administration of ApoE ε3
could provide beneficial effects for some individuals.
Multipotent mesenchymal stromal cells (MSC), also
known as marrow stromal cells or mesenchymal stem
cells, are a heterogeneous population of non-hematopoi-
etic cells representing 0.01–0.001% of the total bone mar-
row [13]. The in vivo function of MSCs remains
controversial, but they are generally regarded as hemat-
opoietic support cells and also a source of progenitors for
structural tissues [14].
The existence of such cells was first suggested by Cohne-
heim in the 1870s [14] but Friedenstein and his col-
leagues were the first to isolate and culture MSCs in the
1970s [15-19], followed by Caplan and colleagues
[20,21] who were the first to propose the phrase "mesen-
chymal stem cells". These cells are adherent to plastic and
are known to differentiate to osteoblasts, chondrocytes
and adipocytes in vitro and in vivo [13,14,22,23]. How-
ever, more recent findings suggest that MSCs may differ-
entiate to additional cell types [23]. Another remarkable
characteristic of MSCs are their immunosuppressive qual-
ities, suggesting that they may survive and engraft in allo-
geneic recipients [13]. Because MSCs are easily expanded
in culture, readily engraft into host tissues, and may
locally modulate the immune response, they represent
ideal candidates for cytotherapy. Specifically, MSCs repre-
sent an extremely useful tool for the treatment of deficits
in ApoE function if harbouring the ApoE ε3 isoform.
In a previous study we demonstrated that murine MSCs
(mMSCs) injected into the lateral ventricles of 4 day old
ApoE null mice secreted small amounts of ApoE into the
tissue [24]. As ApoE null mice mature, the animals
develop cognitive impairment, but upon behavioural
analysis, the presence of mMSCs resulted in improved
cognitive behavioural testing compared to the control
groups [24]. Therefore, human MSCs (hMSCs) seemed a
promising vector for the administration of ApoE ε3 in
human diseases. In contrast to mMSCs, unmanipulated
human MSCs (hMSCs) do not synthesize ApoE mRNA in
vitro, but expression could be observed after 7 days of adi-
pocyte differentiation [25]. Pharmaceutical induction of
ApoE secretion has been demonstrated in macrophages,
hepatocytes, adipocytes and other cell types by a variety of
agents. In two studies employing rat hepatocytes, ApoE
secretion was stimulated using dexamathasone, insulin,
or a combination of both [26,27]. In macrophages, secre-
tion of ApoE was induced by treatment with TGFβ and
dexamethasone [28]. Expression of ApoE mRNA by adi-
pocytes was increased by pioglitazone and ciglitazone,
neither of which affected the ApoE secretion of macro-
phages [29].Page 2 of 17
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enous ApoE expression by hMSCs. We demonstrate here
that dexamethasone alone or adipo-inductive media
(AIM) containing dexamethasone, indomethacin and iso-
butylmethylxanthine resulted in the expression of high
levels of ApoE by hMSCs in vitro. Maximal expression
could be attained after approximately 5–10 days of dex-
amethasone or AIM treatment depending on the donor
source of the cells. We found no correlation between the
ApoE expression levels and the degree of cell expansion
prior to the assay, nor did we find any correlation between
sex or age and ApoE secretion kinetics. The maximal rate
of secretion ranged between 0.004–0.006 ng cell-1 day-1.
After withdrawal of the stimulus, ApoE expression
remained approximately 14 days, but sometimes much
longer, depending on the donor. These in vitro results
demonstrate that ApoE expression by hMSCs is entirely
possible through pharmaceutical induction without the
necessity for genetic manipulation. Therefore, MSCs may
represent a safe and feasible strategy for treatment of dis-
eases that result from a functional deficit of ApoE.
Results
Culture and characterization of human MSCs
We employed MSCs from a total of eight donors for the
study. Human MSCs were recovered from the mononu-
clear fraction of whole bone marrow and cultured as
described in the Materials and Methods. The adherent com-
ponent of the cultures, containing hMSCs is relatively
pure, but frequently contains traces of contaminating
osteoblasts, fibroblasts and senescent cells. To assay for
enrichment of multipotent hMSCs, we performed differ-
entiation assays to osteoblasts, adipocytes and chondro-
cytes. The hMSCs readily differentiated into all three
lineages when subjected to the appropriate conditions
(Figure 1). MSCs formed mineralized osteoblasts as
detected by the calcium binding dye, alizarin red S; they
formed adipocytes with oil red O stainable lipid droplets;
Differentiation of human MSCsFigu  1
Differentiation of human MSCs. Characterization of MSCs by differentiation assays. One donor is presented. Row 1, high 
(right) and low power (left) micrographs of osteogenic MSCs stained with Alizarin Red S for calcium. Row 2, high (right) and 
low power (left) micrographs of adipogenic MSCs stained with oil red O for lipid. Row 3, high (right) and low power (center 
and left) micrographs of toluidine blue (purple) stained sections of MSC pellets induced to form chondrocytes and cartilage. All 
donors were assayed for adipogenesis and osteogenesis with the exception of chondrogenesis, where 2 donors were assayed.Page 3 of 17
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stained purple with toluidine blue when subjected to pel-
let culture in the presence of bone morphogenic protein 2
and tumor necrosis factor β.
Induction of ApoE production
Unmanipulated hMSCs did not secrete detectable levels of
ApoE when the conditioned culture media was assayed by
ELISA as shown in the controls in figures 2, 4, 5 and 6.
Since previous studies have reported successful induction
of ApoE secretion from other cell types, we decided to
screen some candidates for ApoE inducing activity. A total
of nine conditions were tested; 0.5 μM dexamethasone
(Dex), neural stem cell conditioned media (NSC-CM),
AIM, osteogenic media (ost), 30 μM ciglitazone (cig 30),
3 μM ciglitazone (cig 3), 100 μM troglitazone (trog 100),
10 μM troglitazone (trog 10). Confluent MSC monolayers
from 2 donors were cultured in the experimental condi-
tions for 21 days. At 2 day increments, conditioned
medium was recovered for ApoE ELISA. Of the conditions
tested, five induced ApoE expression after 10 days of treat-
ment; these were Dex, NSC-CM, AIM, ost and cig 30 (Fig-
ure 2a). Cig 30 transiently induced ApoE secretion by day
10 of culture but these levels were absent at subsequent
time points. Ost maintained ApoE expression to day 21,
the end point of the experiment, but the levels remained
very low. Since mMSCs were shown to secrete ApoE in
brains of mice [24], we tested conditioned media from
murine neural stem cells. Transient expression of ApoE
was induced after 10 days of culture, but these levels were
undetectable at later time points. Since the ELISA detects
only human ApoE, the levels were derived from the
hMSCs rather than trace levels in the conditioned media
itself. In contrast, Dex and AIM induced high and robust
expression of ApoE, which persisted until the end of the
experiment at 21 days.
To confirm ELISA data, ApoE was also detected in protein
extracts from MSCs treated with Dex, AIM and control
media, containing an appropriate level of vehicle DMSO,
by western blotting. A single band (34 kDa) correspond-
ing to ApoE was present only in the Dex and AIM treated
MSCs (Figure 2b). The position of this band was later con-
firmed by comparison to immunoblotted recombinant
human ApoE (data not shown). To confirm that Dex was
solely responsible for the induction of ApoE secretion, we
tested whether the two additional components of AIM
induced ApoE expression. Isobutyl-methyl xanthine, a
phosphodiesterase inhibitor, and indomethacin, a ligand
of the adipogenesis master-regulator peroxisome prolifer-
ator-activated receptor, both failed to induce ApoE expres-
sion alone or in combination, nor did they induce
terminal adipogenesis (data not shown). Furthermore,
Dex did not appear to induce ApoE as a by-product of ter-
minal adipogenesis, since lipid droplets could not be
detected in long term treated cultures (Figure 2c). Thereaf-
ter, Dex and AIM were the selected conditions for subse-
quent experiments.
Kinetics and Maintenance of ApoE production
To examine the kinetics, longevity, and donor-depend-
ency of the inducible ApoE secretion, a series of time
course experiments were performed with hMSCs from
eight donors. In the first series of experiments, we exam-
ined the rate of response to Dex and AIM in terms of
attaining maximal ApoE secretion. Confluent monolayers
of hMSCs were established from passage 2 (approximately
15 doublings per cell) cultures. Cells were treated with
Dex or AIM and for controls, the cells were treated with
either vehicle (DMSO) or not at all. At 2–3 day intervals,
media were recovered and ApoE levels were measured by
ELISA (Figure 3). For all MSC preparations tested the con-
trol cultures did not secrete ApoE over the entire experi-
mental period (data not shown). For the AIM and Dex
conditions, maximal ApoE expression was attained after
21 days and was sustained for up to 35 days. After long
term culture (about 35 days), the ApoE yield dropped due
to apoptosis of the MSCs that frequently occurs after sus-
tained culture at confluency. The ApoE yields were com-
parable between all of the MSC preparations at about 70–
100 ng day-1 for the Dex (Figure 3a) and 100–140 ng day-
1 for the AIM conditions (Figure 3b). There were no corre-
lations between the rate of response to stimulus and
donor age or sex. When stimulated by Dex only, there was
a linear increase in the rate of ApoE secretion from
hMSCs. However, there was an exponential increase in the
rate of ApoE secretion when treated with AIM and this was
accompanied by differentiation into adipocytes. Since
adipocytes are a source of ApoE in vivo, this probably
accounts for the higher overall ApoE output, and the
accelerated rate of secretion.
The next study was designed to address the longevity of
ApoE secretion after withdrawal of stimulus. Confluent
passage 2 MSC cultures were incubated in Dex and AIM
media for 21 days to attain maximal expression of ApoE.
The cells were then cultured in the absence of stimulus for
an additional 2 weeks (Figure 4). After 2 weeks, ApoE
expression dropped to about 8% of the maximum for AIM
treated cells and the Dex treated cells expressed barely
detectable levels. This suggested that for sustained ApoE
expression, induction is required at least weekly.
In consideration of the prospect of clinical application, we
examined the dose dependency of ApoE induction on
MSCs. Although AIM media was most effective in induc-
ing ApoE secretion by MSCs, the compounds have not
been safely co-administered in vivo. On the other hand,
dexamethasone is a standard therapeutic and would be
acceptable for administration to humans at low doses. WePage 4 of 17
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a – Assays of ApoE productionFigure 2
a – Assays of ApoE production. Some conditions known to induce ApoE production in other cells and their effect upon 
MSCs. NSC conditioned media AIM and osteogenic conditions are also included. Experiment was repeated with 2 donors and 
data from one of the donors is presented, n = 3, average ± standard deviation is shown. b – Detection of ApoE in MSCs by 
western blotting. Western blot demonstrating ApoE (34 kD) production (upper) in early (passage 2, left column) and late (pas-
sage 8, right column) passage MSCs. Lanes were normalized to GAPDH expression (lower). Experiment was repeated 5 
donors. c – Dex-mediated expression of ApoE in MSCs is not accompanied by adipocyte differentiation. ApoE expression by 
MSCs was induced by exposure to Dex or AIM. After 21 days, the monolayers were stained with oil red O to visualize lipid 
droplets (left). Lipid droplets were evident in AIM treated, but not Dex treated MSCs. However, ApoE expression was high in 
both cases when media was assayed by ELISA (right).
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ApoE production kineticsFigure 3
ApoE production kinetics. ApoE production during 21 days of treatment with 0.5 μM dexamethasone (panel a) or adipoin-
ductive media (panel b). Experiment was repeated for 8 donors, data from one donor is presented, n = 3, error bars are stand-
ard deviations.
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to 2 μM and 0.01 μM to 0.1 μM found that the dose of Dex
could be reduced from 0.5 μM to 0.125 μM with insignif-
icant reduction in ApoE secretion (Figure 5a). The lower
dose response series demonstrated that approximately
half maximal ApoE expression could be attained (Figure
5b).
ApoE production and cell number
To provide insights on cell viability and proliferative
potential during induction, we examined ApoE secretion
on a per cell basis. MSCs were allowed to reach 70% con-
fluency before beginning treatment with AIM or Dex.
Media and cells were collected at day 7, 14 and 21. At each
time point, the amount of ApoE secreted per day was nor-
malized to the number of cells in the monolayer. Overall
cell recovery was slightly reduced when compared to the
untreated controls suggesting that DMSO primarily
affected MSC proliferation (data not shown). However,
the presence of Dex and AIM did not affect long term via-
bility, since the cultures slowly expanded over the 21 day
experimental period. In the case of AIM, normalized ApoE
levels reflected the unmodified measurements (Figure 3b)
with a continuous increase in ApoE levels over time sug-
gesting that as the cells divide in culture, they retain their
ApoE secretion potential. In the case of the Dex condi-
tions, normalized ApoE levels dropped slightly, suggest-
ing expansion of some cells with limited or no potential
for ApoE secretion (Figure 6).
We then tested the ability of the ApoE to bind to VLDLs.
To reduce background, ApoE expression was induced for
2 days by Dex treatment in serum free media. MSC viabil-
ity was not significantly affected during the brief exposure
to serum free conditions and ApoE expression occurred at
levels comparable to expression in serum containing
media (Figure 7b). The conditioned media was then incu-
bated with biotinylated VLDLs and then subjected to a
series of biotin-mediated depletions using streptavidin
coated microtiter plates (Figure 7a). Upon ELISA of the
ApoE production following withdrawal of inductive mediaFigure 4
ApoE production following withdrawal of inductive media. MSCs were treated with the inductive media (0.5 μM dex-
amethasone (Dex) or AIM (Adipo)) through for 21 days, then with CCM for a further 2 weeks. ApoE levels drop abruptly after 
day 21. Experiment was repeated 3 donors, data from one donor is presented, n = 3, error bars are standard deviations.Page 7 of 17
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Dose responsesFigure 5
Dose responses. Dexamethasone dose response (high dose, panel a, and low dose, panel b). Experiments were repeated 
with 2 donors, data from one of the donors is presented, n = 3, error bars are standard deviations.
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when compared to controls that were treated identically,
but lacked VLDL (Figure 7b). This suggests that the MSC-
derived ApoE meets at least one of its in vivo functions.
ApoE also binds to the LDL receptor and facilitates inter-
nalization by hepatocytes, macrophages and astrocytes.
To examine the potential of MSC-derived ApoE to acceler-
ate lipid uptake, we generated synthetic micelles contain-
ing fluorescently labelled cholesterol ester and free
cholesterol. When such lipid micelles were added to
serum free media conditioned by the ApoE (Figure 8a), it
bound to them and could be enriched from the media by
centrifugation (Figure 8b). When compared to untreated
controls, the ApoE conditioned media catalysed the for-
mation of larger micelle aggregates, many of which could
be identified by the naked eye (data not shown). Further-
more, ApoE conditioned media accelerated the uptake of
the fluorescent lipid aggregates by huh-7 hepatocytes (Fig-
ure 8c).
Discussion
There are a number of reports where ApoE has been suc-
cessfully administered via direct gene delivery or virally in
a variety of disease models including Alzheimer's disease
[11], hypercholesterolemia [33-36], hyperlipidemia [37],
atherosclerosis [37-39], experimental stroke [40] and
hematopoietic diseases [41]. Direct gene introduction or
direct viral therapy can be efficient and sustainable in
some cases, but it is associated with safety concerns. To
circumvent some of these problems, ApoE has been
administered through hematopoietic stem cells (HSCs) in
rodent models [42-44]. The HSCs are administered to
radioablated animal models and long term hematopoietic
stem cells reconstitute the bone marrow compartment. In
some studies, ApoE is introduced to the HSCs virally, and
in others, the inherent ApoE is utilized mostly through
expression by resultant macrophages. These studies sug-
gest that bone marrow transplantation is a promising vec-
tor for cytotherapeutic ApoE administration but the
process of radioablation in humans is a dangerous proce-
dure, and graft versus host disease is a common problem
with allogeneic recipients. Viral integration, especially
with long term repopulating HSCs is also a source of con-
cern for these strategies.
ApoE production per cellFigure 6
ApoE production per cell. Rate of ApoE production normalized to cell number. Cells were treated with inductive media 
(0.5 μM dexamethasone (Dex) or AIM (Adipo)) for 7–21 days. Experiment was performed on 1 donor, n = 3, error bars are 
standard deviations.Page 9 of 17
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Binding of ApoE to VLDLF gure 7
Binding of ApoE to VLDL. ApoE was secreted into serum free media by MSCs. The conditioned media was then added to 
biotinylated VLDLs (panel a). After biotin depletion, the remaining ApoE in the conditioned medium was measured by ELISA 
(panel b). When compared with buffer alone, biotinylated VLDLs depleted the ApoE from the conditioned medium. Data from 
one of two donors is presented, n = 3, error bars are standard deviations.
BMC Biotechnology 2008, 8:75 http://www.biomedcentral.com/1472-6750/8/75
Page 11 of 17
(page number not for citation purposes)
Binding of ApoE to synthetic micelles and uptake by hepatocyte cellsF gure 8
Binding of ApoE to synthetic micelles and uptake by hepatocyte cells. ApoE was secreted into serum free media by 
MSCs. Fluorescent cholesterol-ester and cholesterol was then added to the media (panel a). Upon recovery of the micelles by 
centrifugation, ApoE could be detected when analyzed by western blotting (panel b). When ApoE conditioned media was 
mixed with lipids and incubated with huh-7 hepatocarcinoma cells, it accelerated uptake when compared with control media. 
Phase contrast/fluorescent merge indicating hepatocytes taking up fluorescent cholesterol (green) from the medium (panel c).
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peutic vector would be beneficial. MSCs are safely recov-
ered from humans via a simple iliac crest aspirate and can
be expanded by the million [22,31]. Their characteristics
suggest that they would be an excellent delivery tool for
ApoE; for instance, when administered into animal mod-
els, they survive for long periods in the brain (up to 6
months) and subcutaneously [24,45-48]. When in the
brain, hMSCs secrete trophic factors that stimulate neural
stem cell proliferation and probably their own survival
[49]. Upon subcutaneous implantation, the hMSCs dis-
tribute themselves close to capillary beds suggesting that
they have the capacity to secrete proteins into the blood
[45]. MSCs are also immunomodulatory, with the capac-
ity to suppress a variety of rejection mechanisms [11],
reducing the possibility of graft versus host complications,
and improving the probability of allogeneic transplant.
Finally, transplanted hMSCs do not rapidly proliferate in
adult tissues in the same way repopulating HSCs do, sug-
gesting that they may also be safer for accommodating
viral transgenes.
In our previous study [24], mMSCs were administered to
the lateral ventricles of ApoE null mice. As they age,
untreated ApoE null mice develop cognitive deficits that
resemble Alzheimer's disease in addition to profound
atherosclerotic pathogenesis. Remarkably, upon adminis-
tration of the murine MSCs, the mice exhibited signs of
improvement in some of the behavioural tests. When the
brains of the experimental animals were examined, a
small amount of murine ApoE could be detected.
Although the presence of other mMSC derived factors
could have contributed to functional recovery, the pres-
ence of ApoE 6 months after MSC administration strongly
suggested that the functional deficit of ApoE in the null
mice had been attenuated. We therefore hypothesized
that hMSCs may provide a promising vector for adminis-
tration of the ApoE3 isoform for the treatment of Alzhe-
imer's disease and possibly atherosclerosis.
We could not detect ApoE expression in vitro, when cul-
tured under standard conditions, nor could we detect
expression when cultured in murine neural conditioned
medium. This was surprising, since administration of
murine MSCs in vivo, stimulated expression. We hypothe-
size that the ApoE null environment may have been suffi-
cient to stimulate expression or more likely, the hMSCs
required contact with the neural cells to initiate expres-
sion. Due to the limited availability of human neural tis-
sue, and in view of potential inter-species incompatibility,
we decided to attempt induction of expression using com-
monly available pharmaceuticals. This approach has been
utilized with a variety of cell lines and a variety of reagents
[26-29] and also in MSCs when differentiated completely
into adipocytes [25]. Administration of adipocytes
directly into the brain cannot be performed, therefore we
tested related conditions in an attempt to induce ApoE
expression without lipid droplet accumulation that occurs
during adipogenic differentiation. In contrast with previ-
ous literature where adipocytes were employed [29],
PPARγ agonists gave very limited success (Figure 2a) dem-
onstrating that the compounds function in a cell type-
dependent manner. Another series of studies demon-
strated efficacy with the hydrocortisone analog, dexame-
thasone on murine macrophages and rat hepatocytes [26-
28]. We therefore tested dexamethasone at the equivalent
concentration employed for adipogenic differentiation
and we achieved high levels of ApoE expression without
complete differentiation into adipocytes. Indomethacin
and Dex also induced ApoE secretion, but we also
observed high levels of unwanted adipogenesis (data not
shown). We acquired the genotype of 2 of the 8 donors
and found them to be Apo ε3/3 and Apo ε2/3. These
donors had comparable ApoE expression levels when
compared with the other uncharacterized MSC prepara-
tions. This confirmed that MSCs with preferable Apo ε3/3
genotype would be compatible with the Dex induction
strategy.
Permanent induction of ApoE would be beneficial, dis-
missing the need for constant drug administration. How-
ever, withdrawal of both Dex and AIM caused a reduction
of ApoE output over 2 weeks. Although it is unclear
whether this is due to outgrowth of a non-expressing com-
ponent of MSCs or due to attenuation of expression, the
extent of proliferation required to completely ablate
expression is not expected in these confluent cultures. Of
interest, is the reduced expression of ApoE in the AIM
treated cultures, which, by day 21 have mostly differenti-
ated into lipid-filled adipocytes. It appears that ApoE is
not a prerequisite for maintenance of the terminal adi-
pocyte phenotype. We did not observe a qualitative reduc-
tion in lipid filled cells suggesting that dedifferentiation
had not occurred, but this phenomenon cannot be com-
pletely discounted.
We found that doses as low as 0.125 μM were sufficient to
maintain maximal expression of ApoE, and doses as low
as 0.01 μM could sustain half maximal levels of ApoE
expression. These levels are comparable with published
therapeutic plasma levels of dexamethasone, which are in
the region of 0.001 – 0.05 μM for immunomodulation
[50]. These results suggest that relatively safe plasma levels
that can be attained clinically would be sufficient for ApoE
induction by implanted MSCs.
Nevertheless, chronic Dex administration is not without
serious side effects [51] such as immunological inhibi-
tion, diabetes/hyperglycemia, osteoporotic symptoms,
gastric irritation, weight loss or gain, glaucoma, musclePage 12 of 17
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effects increase with duration and dose. Since expression
of ApoE was maintained for at least 7 days by hMSCs after
withdrawal of stimulus, it is possible that less frequent
administration of Dex (every 2 days, for instance) may
maintain ApoE levels while reducing the probability of
harmful effects. Furthermore, corticosteroids with faster
clearance and shorter effect durations, such as prednisone
or hydrocortisone may improve the risk/benefit ratio [51].
In terms of efficacy, we found that maximal ApoE expres-
sion per cell was in the region of 0.0033 ng per cell in 24
hr when treated with Dex. Since the plasma concentration
is about 50 mg L-1 [2], and the average blood volume in
an adult human is 5.5 L, it would take an implant contain-
ing 250 million cells about 7 days to attain 1% of normal
systemic ApoE levels, a dose that is protective against
atherosclerotic plaque formation [38]. However, systemi-
cally infused MSCs have the capacity to migrate to sites of
injury and inflammation, suggesting that the local dose of
ApoE might be much higher at the lesions [14,22,23].
Direct injection of a lower dose of MSCs into the brain
may provide long term relief of Alzheimer's disease while
stimulating the local population of neural stem cells to
repair existing damage [49]. In healthy humans, the blood
brain barrier (BBB) is somewhat resistant to Dex penetra-
tion due to multidrug resistance receptor action [52] and
this is a potential problem for treatment of Alzheimer's
disease. There are, however, alternative corticosteroids,
such as prednisolone, which are predicted to have similar
effects and have been reported to have increased permea-
bility into the cerebrospinal fluid [51,53-55]. Further-
more, there is extensive evidence that the BBB is
compromised in individuals with Alzheimer's disease sug-
gesting that Dex may have access to implanted MSCs in
severe cases [56-58].
It can be argued that MSCs may not require pharmaceuti-
cal ApoE induction at all since there have been reports
that they express various neuronal markers in vitro [59]
and in vivo [46,59,60] and thus may spontaneously differ-
entiate into astrocytes in the brain. Indeed, murine MSCs
were shown to express nestin, β-III tubulin, neurofilament
marker and GFAP (an astrocyte marker) in vitro [59], and
GFAP, β-III tubulin, and neurofilament in vivo after trans-
plantation into mice [46,59]. Human MSCs were also
shown to express GFAP [60]in vivo. However, it is note-
worthy that in every instance where MSCs were implanted
into the murine brain, only a small proportion expressed
the astrocyte marker, GFAP. Therefore, although some
hMSCs may differentiate into ApoE-secreting astrcocytes,
it remains important to pre-treat the hMSCs with Dex to
ensure that the majority of the cells secrete ApoE immedi-
ately upon implantation.
Since functional ApoE has been expressed in E. coli [61]
and in insect cells [62], it is likely that the MSC-derived
ApoE is also functional. Nevertheless, we confirmed that
the protein could associate with cholesterol esters and
could also bind to VLDLs (Figure 7 and 8). MSC-derived
ApoE also accelerated uptake of lipid by hepatocytes (Fig-
ure 8). Since the physiological role of ApoE is dependent
binding of lipid and the LDL-receptor, these data suggest
that the ApoE would satisfy its role in vivo. Of particular
note, is the observation that MSCs produce high levels of
ApoE in the absence of serum (Figure 7a). This raises the
possibility of generating ApoE preparations for therapeu-
tic use without the necessity for MSC administration.
Since MSC conditioned media inherently contains neuro-
protective cytokines [49], dialysed conditioned media
containing ApoE may represent an efficacious neuropro-
tective cocktail for clinical use.
Conclusion
In this study we have shown that expression of potentially
therapeutic levels of functional ApoE by hMSCs can be
induced with dexamethasone. These data demonstrate
that co-administration of hMSCs genotyped for
homozygous expression of ApoE ε3 and chronic cortisol
treatment may represent a novel therapy for severe
instances of ApoE related diseases.
Methods
Culture of human multipotent stromal cells
Mutlipotent stromal cells were acquired from the Tulane
University adult stem cell distribution facility. In accord-
ance with institutional review board approved protocols,
the cells were prepared from 2 mL posterior iliac crest
bone marrow aspirates derived from 7 males and 1 female
between 25 and 34 years of age. After a brief interval of
monolayer culture to exclude non-adherent hematopoi-
etic cells, hMSCs were expanded to 70% confluency prior
to passage or use in experiments. Cells were cultured
according to standard MSC culture conditions in com-
plete culture medium (CCM), consisting of alpha mini-
mal essential medium (GIBCO, Invitrogen, Carlsbad, CA)
containing 20% (v/v) FBS (Hyclone, Logan, UT and Alt-
anta Biologicals, Norcross, GA), 2 mM L-glutamine and
100 units ml-1 penicillin and 100 μg ml-1 streptomycin
(GIBCO, Invitrogen) [30,31].
Differentiation of human multipotent stromal cells
To confirm that the cell preparations from the mononu-
clear layer were multipotent, a panel of differentiation
assays were performed.
Osteogenic differentiation and Alizarin Red S staining
For osteogenic differentiation, confluent monolayers of
hMSCs were incubated in CCM supplemented with 10-8 M
dexamethasone, 50 μg mL-1 ascorbic acid and 5 mM β-Page 13 of 17
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changes of medium every 2 days. The monolayers were
then stained with 40 mM Alizarin Red S pH 4.0 (Sigma)
for 30 min and washed 4 times with distilled water.
Micrographs were taken using an inverted microscope
(Nikon Eclipse, TE200).
Adipogenic differentiation and Oil Red O staining
All reagents were purchased from Sigma. Confluent mon-
olayers of hMSCs in 6 well plates (10 cm2 per well) were
incubated in adipoinductive medium (AIM) consisting of
CCM containing 0.5 μM dexamethasone, 5 × 10-8 M iso-
butylmethylxanthine, and 5 × 10-7 M indomethacin
(Sigma). Media was changed every 2–3 days. After 21
days, the adipogenic cultures are fixed in 10% formalin
for 15 min and stained with fresh Oil Red-O solution 0.5
(w/v) (Sigma) in 30% (v/v) isopropanol in phosphate
buffered saline (PBS) for 20 min. The dishes were washed
3 times with excess PBS and visualized using an inverted
microscope (Nikon Eclipse, TE200).
Chondrogenic differentiation and processing
Micromass pellet chondrogenic differentiation was car-
ried out in accordance with the protocol of Sekiya et al. on
200,000 pelleted cells [32]. After 21 days of differentia-
tion, the chondroid pellets were washed in PBS and fixed
in 4% paraformaldehyde. The pellets were then embed-
ded in paraffin, sectioned, then stained with toluidine
blue to visualize sulphated proteoglycans and chondro-
cyte lacunae [31].
ELISA detection of ApoE
Sample preparation for ELISA
hMSCs were plated in each well of a six well plate at 1000
cells per cm2 and grown to 70% confluency. The media
was then changed to the appropriate conditions and
maintained for the appropriate duration with changes
every 2–3 days. All experiments were performed in tripli-
cate. Media samples were taken at intervals defined in the
Results and stored for ELISAs at -20°C. Dexamethasone
and dimethyl sulphoxide (vehicle) were purchased from
Sigma and diluted into CCM from a 1000× stock solution.
AIM and osteogenic media were prepared as described
above and the individual components were added to
CCM from stocks. For production of NSC conditioned
medium, a frozen vial of murine neural stem cells (NSCs,
a gift from Dr Jeffrey Spees, Department of Medicine, Car-
diovascular Research Institute, University of Vermont)
was employed. NSC conditioned medium was produced
by incubation of the NSCs in NSC media [neurobasal
alpha medium containing B27 supplement, L-glutamine,
penicillin, streptomycin (Invitrogen), 10 ng mL-1 epider-
mal growth factor, 10 ng mL-1, fibroblast growth factor
(Sigma)] for 2 days. NSC conditioned medium was mixed
1:1 with CCM prior to addition to the hMSCs. Ciglitazone
was purchased from Tocris Biochemical (Bristol, UK) and
troglitazone was purchased from Cayman Chemical (Ann
Arbor, MI). The drugs were added to CCM from a stock
dissolved in DMSO. All assays were conducted in parallel
with vehicle, or unconditioned media controls.
Human ApoE sandwich ELISA
A polyclonal goat-anti-human ApoE antibody (Academy
Biomedical, Houston, TX) was diluted in PBS at 1:1000.
Each well of a high binding microtiter plate (Fisher Lifes-
ciences) was coated with 100 μL of the antibody solution
for 15 hrs at 4°C. The coating solution was then removed
followed 3 × 5 min washes with 150 μL PBS. Wells were
then blocked by addition of PBS containing 0.1% (v/v)
Tween20 (Fisher Lifesciences) and 5% (w/v) bovine
serum albumin (Sigma) for 2 hrs at room temperature.
Block solution removed and the wells were washed for 3
× 5 min in PBS containing 0.1% (v/v) Tween20 (PBST).
Media samples (100 μL) were added to the wells in tripli-
cate. Standard solutions of recombinant human ApoE
(Calbiochem, Gibbstown, NJ) were diluted in PBST. Sam-
ples were incubated in the microtiter plates for 15 hrs at
4°C. Plates were then washed for 3× for 5 mins in PBST,
and the detection antibody (100 μL) was added consisting
of a 1:2000 dilution of HRP conjugated goat anti human
ApoE IgG (Academy Biomedical) in PBST at room temper-
ature. After 2 hrs, the wells were washed in PBST and
developed by addition of 100 μL TMB (Pierce, Rockford
IL).
After approximately 5 mins, the reactions were stopped
with the addition of 50 μL 2 N sulphuric acid (Fisher Lifes-
ciences) and the resultant yellow substrate was measured
by absorbance (450 nm) on a 96 well plate reader (Fluos-
tar Optima, BMG).
Cell number evaluation
Cells were counted using a DNA intercalating dye that flu-
oresces upon incorporation (CyQuant dye, Invitrogen).
Briefly, monolayers were recovered by trypsinization,
washed in PBS, then resuspended in lysis buffer (PBS con-
taining 0.1% Triton ×100, 1 mM MgCl2) containing a 400
fold dilution of the CyQuant dye. At various dilutions, the
labelling suspensions were aliquoted into a microtiter
plate and fluorescence was measured at 480/525 nm on a
96 well plate reader (Fluostar Optima) using opaque
black plates (Fisher Scientific). Fluorescence was propor-
tional to DNA content, and thus cell number, when com-
pared to known cell standards.
ApoE detection by western blotting
Sample preparation
MSCs were plated on 15 cm plates at 100 cells per cm2 and
grown to 70% confluency. The cells were then maintained
under experimental conditions for 21 days and recoveredPage 14 of 17
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were washed in PBS, flash frozen in liquid nitrogen and
then stored at -80°C for protein extraction. The proteins
were solubilized using an extraction solution consisting of
PBS containing 1 mM MgCl2, 1% (w/v) SDS (Sigma),
0.1% Triton X-100 (Fisher Lifesciences) and 10 fold pro-
tease inhibitor cocktail (Roche Diagnostics, Nutley, NJ).
Protein yield and quality was evaluated by gel electro-
phoresis (Novex electrophoresis system, Invitrogen) fol-
lowed by silver staining (Invitrogen).
Western blot assay
Approximately 30 μg of protein were added to the appro-
priate volume of 2 × LDS-PAGE sample buffer (Invitro-
gen) containing 1 mM β-mercaptoethanol and 2 M urea
(Sigma Aldrich). The samples were heated at 95°C for 5
mins and electrophoresed on a 10% NuPage bis-Tris gel
using the MOPS buffering system followed by transferral
to PVDF for 7 min (iBlot, Invitrogen). Filters were blocked
in PBS-T containing 5% (w/v) powdered milk (Santa Cruz
Biotechnology, Santa Cruz, CA) for 2 hrs. For detection of
ApoE the blots were incubated overnight in an HRP con-
jugated goat anti human ApoE (Academy Biomedical) at
1:500 in block buffer. For detection of GAPDH, blots were
probed with a monoclonal antibody at a dilution of
1:1000 (clone 6C5, Chemicon, Temecula, CA). For sec-
ondary detection, a rabbit anti-mouse IgG antibody cou-
pled to horse radish peroxidase was used at a dilution of
1:1500 (Sigma). The blots were developed in peroxidase
substrate (100 mM Tris pH 8.0 containing 75 μM para-
coumaric acid, 500 μM luminol and 0.006% (v/v) hydro-
gen peroxide, Sigma) for 5 mins prior to exposure to
photographic film (Pierce).
VLDL binding assay
MSCs were transferred to serum free complete culture
medium containing Dex or vehicle. After 2 days, the con-
ditioned medium was filtered through a 0.2 μm mem-
brane. One mL of the conditioned medium was added to
50 μg of biotinylated human VLDL solution (Intracel, Fre-
drick, MD). The mixture was incubated for 4 hr with rota-
tion, and large VLDL aggregates were removed by
centrifugation at 15,000 g for 15 min. The mixture was
then depleted of biotinylated components by 4 sequential
30 min incubations in wells of a streptavidin coated
microtiter plate (Streptawell High Bind, Roche Diagnos-
tics). The supernatant was then subjected to ELISA assay.
Production and characterization of lipid micelles 
containing labelled cholesterol ester, cholesterol and MSC 
derived ApoE
Conditioned serum free medium containing 50–100 ng
mL-1 ApoE was incubated in 50 μg mL-1 4,4-difluoro-5-(2-
pyrrolyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoate
(cholesteryl BODIPY 576/589 C11, Invitrogen), and 5 μg
mL-1 25-[N-[(7-nitro-2-1,3-benzoxadiazol-4-yl)methyl]
amino]-27-norcholesterol (NBD cholesterol). Cholesteryl
BODIPY 576/589 C11 is a blue cholesteryl ester and NBD
cholesterol consists of a cholesterol moiety covalently
conjugated to a green fluorophore 460/534. Lipids were
allowed to self-assemble at 21°C with slow mixing. In
some cases, the micelles were recovered by centrifugation,
washed in ice cold PBS and assayed for ApoE content by
western blotting. For cell binding studies, Huh-7 hepato-
cytes (a gift from Srikanta Dash, Tulane Health Sciences
Center) were expanded in 6 well plates containing stand-
ard media at 37°C with 5% (v/v) CO2. Upon initiation of
the experiment, 2 mL of micelle-containing serum free
medium was added to the cultures and at hourly intervals,
cultures were washed in warm PBS, then the medium was
replaced by serum free medium without lipid. Cells were
visualized by epifluorescent and phase microscopy. Kinet-
ics of the uptake of NBD cholesterol was compared
between ApoE containing and vehicle containing control
media.
Statistical Analyses
Measurements were performed in triplicate for each
media sample taken and measurements were considered
acceptable when the variation was less than 5% of the
value. For each condition tested, 3–6 replicate cultures
were prepared and assayed. Data were presented as the
mean of the measurements from replicate cultures with
standard deviations. Representative data are presented
from one donor in figures, but multiple donors were
assayed yielding the same results.
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